Cargando…
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional therapies. Here, we explored whether human T cells that ar...
Autores principales: | Herrmann, Ines, Baeuerle, Patrick A., Friedrich, Matthias, Murr, Alexander, Filusch, Susanne, Rüttinger, Dominik, Majdoub, Mariam W., Sharma, Sherven, Kufer, Peter, Raum, Tobias, Münz, Markus |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956687/ https://www.ncbi.nlm.nih.gov/pubmed/20976159 http://dx.doi.org/10.1371/journal.pone.0013474 |
Ejemplares similares
-
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
por: Deisting, Wibke, et al.
Publicado: (2015) -
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
por: Münz, Markus, et al.
Publicado: (2010) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007) -
EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)